Intercept Pharmaceuticals Investor Relations Material
Latest events
Q2 2023
Intercept Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Intercept Pharmaceuticals Inc
Access all reports
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, is developing obeticholic acid (OCA), an agonist of the farnesoid X receptor, which is in Phase III clinical trials for the treatment of primary biliary cirrhosis; OCA that is in Phase IIb clinical trials for treating nonalcoholic steatohepatitis; and OCA that is Phase II clinical trial to treat fibrosing cholestatic hepatitis. The company was incorporated in 2002 and is headquartered in New York, New York.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
ICPT
Country
🇺🇸 United States